NCT04056910: Phase II Trial of Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: IDH
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a documented IDH1 gene-mutated disease
Exclusions: Patients with known symptomatic brain metastases requiring steroids- see trial for details; Patients who have received prior checkpoint therapy (anti-PD1/L1 or anti-CTLA4 antibody) or prior IDH inhibitor

Comments are closed.

Up ↑